News|Articles|June 18, 2025

ADA 2025 Late-Breaking Trials Preview

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

The 2025 American Diabetes Association (ADA) Scientific Sessions aim to capture the accelerating pace of innovation in diabetes and obesity care. Following a year marked by major clinical milestones, this year’s meeting, taking place June 20–24 in Chicago, brings forward a wave of late-breaking data and pivotal phase 2 and 3 trial results that could reshape treatment standards across the metabolic disease spectrum.

Related to this article

November 5th, 2026

Once-Daily Trientine Tetrahydrochloride Aids Adherence in Wilson Disease

In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.

November 5th, 2026

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

November 5th, 2026

Real-World Odevixibat Data Show Pruritus Relief in Late-Onset PFIC

In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.

November 5th, 2026

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.

November 5th, 2026

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.

Pegcetacoplan Maintains C3G Response at 76 Weeks, With Carla Nester, MD

November 5th, 2026

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

November 5th, 2026

Real-World Resmetirom Data Show Liver Stiffness Gains in MASH

Real-world data at AASLD 2026 show 37% to 55% of patients with MASH on resmetirom (Rezdiffra) improved liver stiffness by 25% or more at about one year.

November 5th, 2026

IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC

In the phase 3 IDEAL trial, 3 in 4 patients with PBC and ALP below 1.67× ULN reached ALP normalization on seladelpar at 52 weeks, compared with 16.1% on placebo.